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A progesterone-brown fat axis is 
involved in regulating fetal growth
Saraid McIlvride1, Aleena Mushtaq1, Georgia Papacleovoulou1, Chloe Hurling1, Jennifer Steel  2, 
Eugène Jansen3, Shadi Abu-Hayyeh1 & Catherine Williamson1
Pregnancy is associated with profound maternal metabolic changes, necessary for the growth and 
development of the fetus, mediated by reproductive signals acting on metabolic organs. However, the 
role of brown adipose tissue (BAT) in regulating gestational metabolism is unknown. We show that BAT 
phenotype is lost in murine pregnancy, while there is a gain of white adipose tissue (WAT)-like features. 
This is characterised by reduced thermogenic capacity and mitochondrial content, accompanied by 
increased levels of markers of WAT and lipid accumulation. Surgical ablation of BAT prior to conception 
caused maternal and fetal hyperlipidemia, and consequently larger fetuses. We show that BAT 
phenotype is altered from day 5 of gestation, implicating early pregnancy factors, which was confirmed 
by reduced expression of BAT markers in progesterone challenged oophorectomised mice. Moreover, 
in vitro data using primary BAT cultures show a direct impact of progesterone on expression of Ucp1. 
These data demonstrate that progesterone mediates a phenotypic change in BAT, which contributes to 
the gestational metabolic environment, and thus overall fetal size.
Pregnancy is associated with a gradual metabolic shift from normal maternal serum concentrations of triglycer-
ides, free fatty acids, and glucose at the time of conception to hyperlipidemia and insulin resistance in the third 
trimester. These changes support the growth and development of the fetus. The importance of maternal-fetal 
energy transfer is exemplified by several pathophysiological conditions. Under-nutrition or obesity during preg-
nancy can increase the risk of babies being born with intrauterine growth restriction or large for gestational 
age1–4. Furthermore, altered metabolism as a result of maternal obesity is associated with an increased risk of 
gestational diabetes and pre-eclampsia5–7, and predisposes the infant to metabolic disease in later life8–10.
Maternal lipid homeostasis is dependent upon the coordination of metabolically active organs. For exam-
ple, during early pregnancy, increased insulin sensitivity in white adipose tissue (WAT) results in lipid accu-
mulation, whereas towards term, in conjunction with placental hormones, there is insulin resistance and lipid 
catabolism11. However, little is known about the prevalence and function of brown adipose tissue (BAT) during 
pregnancy. Adult humans possess classical brown adipocytes and beige cells of white adipocyte origin, both of 
which are thermogenic and can contribute to whole body energy metabolism (reviewed in ref. 12). Interestingly, 
women have been found to possess larger volumes of BAT than men13,14. It is not known whether BAT is involved 
in regulating the gestational metabolic profile. Nonetheless it has been hypothesised that there is a decrease in 
BAT-mediated energy expenditure during pregnancy to divert energy to the developing fetus and/or lactation 
(reviewed in refs 15 and 16), although the data to support this are inconsistent. Research into the effects of repro-
ductive hormones on BAT in the context of pregnancy has largely focused on estrogen17, 18 with limited studies of 
progesterone and prolactin19, 20.
In this report, we examine the impact of pregnancy on BAT, the role of BAT in regulating the maternal and 
fetal metabolic environment, as well as alterations in BAT phenotype mediated by early pregnancy signals.
Results
BAT undergoes morphometric and functional changes during pregnancy. To understand the 
impact of brown adipose tissue (BAT) on pregnancy, a period associated with profound metabolic change, we 
first identified a point during gestation to study BAT biology that follows significant alterations in serum lipid 
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concentrations. Longitudinal sampling of sera over the course of pregnancy identified gestational day (GD) 
14 as a point that follows significant increases in serum cholesterol, HDL, and triglyceride concentrations (see 
Supplementary Fig. S1); fasting serum glucose concentrations were not different at this time point (data not 
shown). Interscapular BAT (iBAT) normalised against total body weight without the uterine horn was found to 
be significantly heavier by 52% at GD14 relative to non-pregnant controls (GD0) (Fig. 1A, and Supplementary 
Figure S2). H&E staining and lipid biochemical analyses revealed that the iBAT at GD14 contained enlarged lipid 
droplets (Fig. 1B), and that there was a 4-fold increase in triglyceride (TG) concentrations, respectively (Fig. 1C). 
iBAT cholesterol and free fatty acids (FFA) concentrations were unchanged. Profiling of classical phenotypic 
markers of brown and white adipose tissue revealed significantly decreased relative gene expression of BAT mark-
ers Ucp1, Dio2, Zic1, and Cidea, accompanied by significant increases in white adipose tissue (WAT) markers 
Lep and Adrp. Gene expression of the β3-adrenergic receptor was unchanged (Fig. 1D). Immunohistochemical 
analysis of GD14 BAT revealed decreased levels of UCP1 (Fig. 1E). Cumulatively, these data point to a decrease in 
overall BAT phenotype accompanied by ‘whitening’ of the tissue at GD14.
To test whether the reduction of BAT phenotype translated to a decrease in basal and inducible thermogenic 
BAT function, indirect calorimetry was used to measure O2 consumption in terminally anaesthetised mice at 
GD14. Basal O2 consumption was found to be significantly higher than at GD0 (Fig. 1F). However, pregnancy 
at GD14 significantly blunted the acute response to the β3-adrenergic receptor agonist norepinephrine (NE), as 
inducible O2 consumption was reduced by 49% (Fig. 1G) and the respiratory exchange ratio by 7.3% (Fig. 1H). 
Relative iBAT mitochondrial Cox2 DNA levels were significantly decreased at GD14, and mRNA expression of 
the mitochondrial gene Nd5 was also markedly reduced, albeit not significantly (Fig. 1I,J). Taken together with 
the UCP1 expression result, these data indicate reduced BAT thermogenic capacity.
Ablation of maternal BAT perturbs gestational metabolism and fetal growth. We hypothesised 
that the gestational loss of classical BAT phenotype and function with accompanied whitening is involved in 
supporting the maternal and fetal metabolic environment. A surgical approach was employed to ablate the inter-
scapular BAT depot (iBATx) of female mice prior to conception, to enable assessment of the relative contribution 
of BAT to gestational metabolism. Gestational days 14 and 18 were chosen as time points of interest to capture 
the impact of BAT ablation prior to, and at the end of, the period of rapid fetal growth and development (Fig. 2A). 
Ablation of BAT had no effect on maternal weight; however, serum cholesterol levels were significantly increased 
by 29.7% at GD18 (Fig. 2B,C). Serum triglycerides, FFA and fasted glucose levels remained unchanged (see 
Supplementary Fig. S3). In the BAT-ablated group, maternal hepatic triglycerides were increased by 17.6%, 27.2% 
and 30.0% at GD0, GD14 and GD18, respectively, although the change was only significant for GD14 (Fig. 2D). 
No differences were observed in liver cholesterol and FFA levels (see Supplementary Fig. S3). Importantly, there 
was no evidence of compensatory ‘browning’ of WAT in the iBATx mice (see Supplementary Fig. S5).
The impact of BAT ablation on fetal parameters was evident at GD18, as the average fetal and placental 
weight increased by 7.8% and 12.3% respectively (Fig. 2E,F), whereas at GD14 no differences were observed (see 
Supplementary Fig. S4). Therefore, at a macroscopic level, fetal growth is influenced by maternal BAT. There was 
no significant difference in the average number of fetuses per pregnancy between the two groups at GD18 indicat-
ing that the increase in fetal and placental weight in the iBATx group is due to the decrease of a factor or function 
associated with brown fat during pregnancy (Fig. 2G).
Ablation of maternal BAT perturbs maternal and fetal lipid homeostasis. The mouse fetus under-
goes a rapid growth phase between GD14 and parturition, which coincides with our observation that at GD18, 
the fetuses are heavier from iBATx mothers. This may be as a result of altered fetal or maternal lipid homeo-
stasis and fuel availability. Biochemical analysis of FFA concentrations in the serum of fetuses at GD18 from 
iBATx mothers revealed a significant increase of 117% (Fig. 3A), whereas triglyceride and total cholesterol levels 
remained unchanged. GD18 fetal hepatic cholesterol concentrations were significantly increased by 11.4% and 
there was a trend for increased FFA in the iBATx group (Fig. 3B).
To determine the source of the increased FFA levels, the expression of genes involved in lipid metabolism 
was studied in GD18 fetal and maternal liver as well as placenta. Fatty acid gene expression targets were either 
unchanged or significantly decreased, e.g. Srebp1c and Acc1 in the fetal liver (Fig. 3C). The expression of placental 
lipases was studied, as they may be involved in the hydrolysis of serum triglycerides to fatty acids, which are trans-
ported across into the fetoplacental unit. Indeed, the expression of Lpl and Hsl were significantly increased by 2.3- 
and 1.6-fold respectively (Fig. 3D). There was a trend for increased gene expression of maternal hepatic enzymes 
Acc1 and Scd1 involved in generating FA in iBATx mothers (Fig. 3E). These data suggest that the increased FFA 
in the fetuses from the iBATx mice is not due to de novo lipogenesis, but rather increased transport across the 
placenta as indicated by the upregulation of placental lipolysis.
Early gestational alterations in BAT phenotype are mediated by a progesterone signal. To 
delineate the gestational signal that alters the BAT phenotype, the expression profiles of BAT and WAT mark-
ers were studied in the iBAT from pregnant mice at GD5 and GD7, pre-placentation time points, and GD11, 
post-placentation. Ucp1 and Dio2 gene expression was reduced considerably from as early as GD7, and Zic1 was 
significantly reduced from as early as GD5, indicating that pre-placentation factors are involved in mediating ges-
tational gene expression changes in BAT. The gene expression of the WAT marker leptin was markedly decreased 
at GD5 and GD7, returning to control levels by GD11. The gene expression of the WAT marker adiponectin 
did not change at the time-points studied (Fig. 4A). These data are supported by the fact that BAT weight is 
unchanged at GD5 (see Supplementary Fig. S6), therefore lipid accumulation does not occur until the later stages 
of pregnancy. To identify the pre-placentation hormone that is able to mediate the early gestational changes in 
BAT phenotype, an in vitro approach was taken. Differentiated primary brown adipocytes were treated with 
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Figure 1. Pregnancy mediates changes in the morphometry and function of BAT. (A) Interscapular BAT 
(iBAT) weight expressed as a percent of total body weight without uterine horn at gestational days 0 (GD0) 
and 14 (GD14). (B) H&E staining of iBAT. Scale bar, 100 µm. (C) Concentrations of total cholesterol (Chol), 
free fatty acids (FFA) and triglycerides (TG), normalised to protein, in iBAT. (D) Expression of genes related to 
BAT and WAT phenotype. (E) Immunohistochemical staining for UCP1 in iBAT. Scale bar, 100 µm. (F) Basal 
measurement of O2 consumption in terminally anaesthetised mice. (G) Measurement of norepinephrine (NE)-
mediated O2 consumption in terminally anaesthetised mice over time with O2 consumption total area under 
the curve. To facilitate comparisons, responses are expressed as increases over pre-NE values. (H) NE-mediated 
changes in respiratory exchange ratio (RER) over time with RER total area under the curve. (I) qPCR analysis of 
DNA levels of mitochondrial Cox2 normalised to nuclear β-actin in iBAT. (J) Expression of the mitochondrial-
encoded gene Nd5 in iBAT.
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500 nM progesterone or 550 ng/ml prolactin overnight, which are physiological concentrations10, 21, ± a 2 hour 
treatment with 1 μM of the β3-adrenergic agonist NE. Ucp1 gene expression was used as a quantifiable reporter 
due to it being a functional marker of brown adipose tissue and because its induction is measurable following a 
2-hour acute challenge. Progesterone significantly inhibited NE-mediated induction of Ucp1 by 49%, whereas 
prolactin did not exert any significant effects (Fig. 4B). This result demonstrated that the pre-placentation hor-
mone progesterone can blunt the induction of the BAT marker Ucp1. Finally, we sought to recapitulate the in vitro 
data in an in vivo model. Exogenous progesterone was administered chronically over two weeks by an osmotic 
pump to oophorectomised mice, which resulted in a significant relative reduction in the expression of Ucp1, Dio2 
and Zic1. There was a trend for prolactin to inhibit Ucp1 and Zic1 expression, but not to the extent of progesterone 
(Fig. 4C), the concentration of which rises early in pregnancy (see Supplementary Fig. S7). Concentrations of 
cholesterol, triglycerides, FFA and glucose, as well as mouse weight were unchanged (data not shown).
These data are consistent with progesterone being the endocrine signal that mediates the gestational changes 
in BAT phenotype.
Figure 2. Surgical ablation of interscapular BAT alters maternal and fetal metabolic profiles. (A) Schema 
summarising the key stages of mouse pregnancy over time and the time-points selected for the study of 
pregnancy and metabolism in iBAT ablated (iBATx) or sham-operated mice, as indicated by the arrows. (B) 
Maternal weight without uterine horn (Sham, n = 5–10; iBATx, n = 6–9). (C) Maternal serum cholesterol levels 
(Sham, n = 6–9; iBATx, n = 7–10). (D) Maternal liver triglyceride levels (Sham, n = 7–10; iBATx, n = 9–12). 
Data are represented as mean ± SEM, *p<0.05 for Sham versus iBATx comparison at a single pregnancy time-
point as determined by unpaired Student’s t-test. (E) Weight of fetuses at GD18 (Sham, n = 46 fetuses from 7 
mothers; iBATx, n = 51 fetuses from 9 mothers). (F) Weight of placentas at GD18 (Sham, n = 24 placentas from 
4 mothers; iBATx, n = 25 placentas from 5 mothers). (G) Average number of fetuses per pregnancy at GD18 
(Sham n = 7; iBATx n = 9). *p<0.05 as determined by unpaired Student’s t-test.
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5ScIentIfIc REPORTS | 7: 10671  | DOI:10.1038/s41598-017-10979-7
Discussion
Fluxes in energy metabolism during pregnancy are vital for the controlled growth of the developing fetus. We 
have demonstrated throughout this study the importance of pregnancy-mediated adaptations to BAT, which 
contribute to the regulation of energy metabolism in both the mother and the fetus. We conclusively show at a 
macroscopic level that the iBAT was hypertrophied at GD14 of pregnancy due to an increase in triglyceride con-
centrations and lipid droplet size. This was accompanied by a decrease in the levels of markers of classical BAT 
phenotype and a parallel increase in WAT markers, giving the tissue a whitened phenotype.
To ascertain if the diminished BAT phenotype resulted in decreased BAT function, we assessed the capacity 
of β3-adrenergic agonist-stimulated thermogenesis at GD14 using indirect calorimetry, avoiding the muscular 
contribution to O2 consumption by terminally anaesthetising the mice. As previously reported22, we observed 
that basal O2 consumption was greater during pregnancy, which may be a consequence of increased metabolic 
activity associated with maintaining pregnancy. However, we demonstrated that norepinephrine-mediated O2 
consumption was blunted at GD14, despite the higher basal O2 consumption. This was paralleled by a reduction 
in the norepinephrine (NE)-mediated RER value. The levels of mitochondrial markers were also reduced at GD14 
and, when combined with reduced UCP1 expression and increased lipid concentrations, could be responsible 
for the abrogation of BAT function during pregnancy. These results demonstrate that BAT undergoes adaptive 
changes characterised by a loss of classical thermogenic phenotype and function accompanied by whitening 
during pregnancy. Similarly, whitening of BAT with a loss of BAT phenotype and function has been observed in 
diet-induced obese mice23.
Evidence for a functional role of gestationally modified BAT was provided by experiments where iBAT, which 
represents approximately 60% of total BAT24, was surgically ablated prior to conception. Days 14 and 18 of gesta-
tion were chosen to study the impact of BAT ablation, as they lie before and towards the end of the period of rapid 
fetal growth25, 26. Removal of BAT had no effect on maternal body weight. This is not surprising, as mice lack-
ing UCP1 housed below thermoneutrality do not become obese and O2 consumption remains unchanged27–29. 
However, the iBATx group had significantly higher levels of serum cholesterol and hepatic triglyceride concentra-
tions. This is consistent with the view that gestationally adapted BAT contributes to whole body lipid metabolism 
during pregnancy.
Figure 3. Surgical ablation of maternal interscapular BAT results in fetal hyperlipidemia. Serum concentrations 
(A) and normalised hepatic levels (B) of total free fatty acids (FFA), triglycerides (TG) and total cholesterol 
of GD18 fetuses from sham-operated (n = 4) or iBATx (n = 5–6) mothers. Expression of genes related to lipid 
homeostasis in (C) GD18 fetal liver (n = 4 per group), (D) GD18 placenta (Sham, n = 7; iBATx, n = 10)) and (E) 
GD0 and 18 maternal liver (Sham, n = 6–7; iBATx, n = 7–8). Liver and serum were pooled from fetuses from 
the same mother. Data are represented as mean ± SEM, *p<0.05 as determined by unpaired Student’s t-test.
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It is well established that the metabolic status of the mother can affect the developing fetus30–33. We therefore 
studied the consequences of iBAT ablation on the fetal compartment. Fetal and placental weight were increased at 
GD18 in the iBATx group as a result of a decrease of a factor or function associated with brown fat during preg-
nancy that contributes to the regulation of fetal growth. There are striking similarities between maternal obesity, 
which is associated with hypertriglyceridemia and an increased risk for babies to be born large-for-gestational 
age4, 7, 31, 34, 35, and our findings in iBAT ablated mice that have raised maternal hepatic triglyceride levels and 
heavier GD18 fetuses. This emphasises the importance of BAT in regulating systemic maternal lipid levels during 
a critical period of fetal development.
Biochemical analyses of the serum from the iBATx GD18 fetuses revealed elevated FFA which is likely respon-
sible for the increased placental and fetal weight. Indeed, FFA are readily converted to precursors of other mol-
ecules that modulate cell growth and metabolism, and incorporated into cellular structures36. We hypothesised 
that the increased FFA levels originated from the maternal serum, as gene expression analysis of lipid home-
ostasis targets in the fetal liver were not increased and, in some cases, were reduced, possibly as a measure to 
rebalance the elevated fetal serum FFA levels. The probable source of the increased fetal serum FFA is hydrolysed 
triglycerides from the placenta, as the expression of placental lipases was significantly increased in GD18 iBATx 
mice. This may be a homeostatic response to reduce the elevated levels of GD14 maternal triglycerides (Fig. 2D), 
emphasising the sensitive nature of the maternal-fetal lipid metabolic axis and the important role BAT plays in 
this. iBATx fetal liver cholesterol concentrations were also significantly increased at GD18, reflecting the GD18 
iBATx maternal hypercholesterolemic environment and increased levels of the placental cholesterol transporter 
Abcg1. However, GD18 iBATx fetal liver gene expression targets involved in cholesterol synthesis were decreased, 
indicating a homeostatic response to the aberrant hepatic cholesterol concentrations. The data presented here 
show a direct link between maternal BAT activity and fetal energy metabolism and growth. A recent study in 
humans has proposed that there is a crosstalk between maternal BAT and fetal adiposity37. In light of our study, 
the impact of maternal BAT ablation upon offspring metabolism in the long term warrants further investigation, 
particularly since adipogenesis is a potential target for fetal programming38.
Pregnancy factors, including reproductive hormones, alter a range of physiological systems to adapt them to 
the gestational needs of the mother and fetus. The impact of pregnancy hormones on BAT has been studied exten-
sively, but the data are conflicting. Estrogen has been shown to both increase and decrease BAT activity17, 18, 39–41. 
This may be a reflection of species and strain specific differences as well estrogen delivery strategies used. In 
addition, previous studies of progesterone and prolactin effects indicate that both hormones can influence BAT 
phenotype and activity19, 42–47. In this study, we investigated three different model systems to identify an early 
gestational signal capable of eliciting phenotypic changes in the BAT seen during pregnancy. Firstly, by studying 
the temporal expression of BAT markers at different stages of pregnancy, we were able to define GD5 and GD7 
as time-points where the expression of classical BAT markers Ucp1, Dio2 and Zic1 were reduced. At GD5 and 
GD7, the gestational factors are likely to be pre-placentation hormones secreted by the ovary and pituitary gland 
such as progesterone and prolactin respectively, whereas post-placentation, GD10 onwards, would include hor-
mones secreted from the placenta, such as estrogen. The expression of the WAT markers leptin and adiponectin 
Figure 4. Progesterone mediates a reduction in the expression of thermogenic genes in brown adipose tissue. 
(A) Expression of genes related to BAT and WAT in iBAT at GD0 (n = 4), GD5 (n = 5), GD7 (n = 5) and GD11 
(n = 5). (B) Relative Ucp1 expression of cultured BAT following treatment with 1 μM norepinephrine (NE) ± 
500 nM progesterone (P4) or 550 ng/ml prolactin normalised to the 1 μM norepinephrine treated group (n = 4). 
(C) Normalised relative gene expression of BAT targets in oophorectomised mice challenged with vehicle 
(n = 7), progesterone (n = 6) or prolactin (n = 6) for 14 days via osmotic pumps. All data are represented as 
mean ± SEM. *p<0.05 as determined by one-way ANOVA.
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were not increased, revealing that gestational whitening of BAT, as observed at GD14, follows the reduction in 
the expression of classical BAT markers. Differentiated primary BAT cultures were treated with physiological 
concentrations of progesterone or prolactin in combination with the β3-adrenergic agonist NE. NE-mediated 
Ucp1 induction was consistently blunted by the progesterone treatment, demonstrating that progesterone is a 
pregnancy signaling molecule that can act on brown adipocytes to modulate the expression of thermogenic tar-
gets. This result is also strongly indicative of a direct effect of progesterone on the brown adipocyte. Finally, the 
expression of Ucp1, Dio2 and Zic1 were all reduced by exogenous progesterone delivered by osmotic pumps 
in oophorectomised mice reconfirming that progesterone is a key gestational signal involved in altering BAT 
phenotype. This is the first study to show that the reproductive hormone progesterone consistently decreases 
BAT phenotype and is therefore a key mediator of the gestational metabolic switch. To corroborate our findings, 
experiments would be required to show that maternal BAT does not change in the absence of progesterone. 
However, due to the physiological importance of progesterone in maintaining pregnancy, these studies are not 
feasible. Further work is needed to investigate whether our findings have implications for use of progesterone in 
in vitro fertilisation techniques, or for women taking progesterone supplements as hormonal contraception or for 
the prevention for pre-term birth.
Human studies have shown that women possess greater volumes of BAT relative to men, which decrease 
with age14, yet few studies have sought to understand why this may be. The data presented here demonstrate that 
the early gestational factor progesterone switches the phenotype of brown adipose tissue, which is necessary to 
support the maternal and fetal metabolic milieu. Moreover, this is the first study to our knowledge that demon-
strates a direct relationship between maternal BAT activity and fetal growth. These data support the notion that 
BAT has an underappreciated gender-specific role in women that has evolved to modify lipid metabolism during 
pregnancy, and underscores BAT as a potential therapeutic target of maternal obesity and as a consequence, fetal 
macrosomia.
Methods
Animal studies. Animal studies were performed using C57BL/6 mice from Charles River UK Ltd., main-
tained on a standard breeding diet (RM3) and allowed free access to food and water. They were housed in stable 
conditions (12 hour light/dark cycle; 22–24 °C). Mice were acclimatised to the animal house for 1 week prior to 
experiments.
For pregnancy experiments, 7–8 week old female mice were mated with males. Virgin mice were used as 
controls (gestational day (GD) 0). GD1 was considered to be the day the copulatory plug was identified. For all 
animal studies, mice were sacrificed after a 4 hour fast, and maternal and fetal serum and tissues were collected 
and snap-frozen immediately or fixed in 10% neutral buffered formalin for 24 hours.
Metabolic studies. Indirect calorimetry was carried out using the LabMaster cage system (TSE). GD0 and 
GD14 mice were terminally anaesthetised by intraperitoneal injection of 90 mg/kg pentobarbital (Merial Animal 
Health Limited). Once fully sedated, they were placed in the metabolic cages and allowed to acclimatise for 
20 minutes, to establish a constant metabolic baseline. Norepinephrine (NE; 1 mg/kg; Sigma-Aldrich) was then 
administered by subcutaneous injection at the nape. The O2 consumption and CO2 production was measured in 
each cage sequentially every 12 minutes, and retrospectively corrected for body weight without pups. Respiratory 
exchange ratio was calculated according to manufacturer’s software.
BAT ablation surgery. 7–8 week old female mice were anaesthetised via isoflurane vapour (Abbott Animal 
Health) and the interscapular BAT (iBAT) was surgically removed. Sham-operated mice underwent the same 
procedure without the removal of iBAT. Mice were single-housed for 2 weeks during the recovery period, and 
then paired with males until visual confirmation of a plug, following which they were monitored until sacrifice at 
GD14 or GD18 of pregnancy, along with GD0 controls.
Osmotic pump implant surgery. 7–8 week old female mice were anaesthetised via isoflurane vapour and 
underwent bilateral oophorectomy. After a two-week recovery period, the mice were anaesthetised and 14-day 
release osmotic minipumps (Alzet model 2002; Charles River) were implanted subcutaneously in the dorsal 
region. Osmotic pumps contained progesterone (250 µg/day; Sigma-Aldrich), prolactin (7 µg/day; PeproTech) or 
vehicle only (20% (w/v) 2-hydroxypropyl-beta-cyclodextrin, Sigma Aldrich). After 2 weeks, animals were sacri-
ficed as described above.
Histology and immunohistochemistry. Fixed iBAT sections were embedded in paraffin and sectioned at 
5 µm onto poly-L-lysine coated slides. Sections were stained with haematoxylin and eosin for histological analysis. 
Immunohistochemical analysis was performed as previously described48. Sections were incubated overnight at 
4 °C with rabbit anti-mouse primary antibody to UCP1 diluted 1:10,000 in phosphate buffered saline. The UCP1 
antibody was a kind gift from Barbara Cannon.
Lipid measurements. Serum and tissue cholesterol, LDL-cholesterol, HDL-cholesterol, TG, FFA and total 
proteins were measured using an Unicel DxC 800 autoanalyzer (Beckman-Coulter) using dedicated kits from 
Beckman-Coulter, excluding FFA which were measured using a kit from Wako Diagnostics (Neuss). Liver and 
brown adipose tissue were extracted in a 0.125 M potassium phosphate buffer and normalised to the total protein 
content.
Primary adipocyte culture and differentiation. iBAT was removed from 10 day old C57BL/6 pups and 
pooled. Primary adipocytes were isolated and differentiated as previously described49. Cells were seeded and 
grown in growth media consisting of DMEM/10% NCS with (final concentrations) 20 nM insulin (Actrapid, 
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Novonordisk) and 1nM triiodothyronine (Sigma-Aldrich), until 70% confluent. The adipocytes were differenti-
ated for 48 hours in the above media supplemented with 500 µM isobutylmethylxanthine, 2 µM dexamethasone, 
50 µM indomethacin and 1 µM rosiglitazone (Sigma-Aldrich). On the morning of an experiment the media was 
replaced with growth media.
mRNA analysis. Total RNA was extracted from frozen tissue using the RNeasy Mini Kit (Qiagen), and 
cDNA synthesised using the Superscript II kit (Thermo Fisher Scientific), according to manufacturer’s instruc-
tions. Semi-quantitative real-time PCR with SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich) was used 
to detect and amplify target cDNA. Relative gene expression was calculated using the ∆∆ Ct method. Genes of 
interest were normalised to the housekeeping gene Cyclophilin B. See Supplementary Experimental Procedures 
online for a table of primers and sequences. Basal expression of Ucp1 was undetectable in several of the cultures, 
and thus the results of the hormonal treatments were calculated as relative to the NE treated group, as previously 
described43 (see Supplementary Fig. S8 for example).
Mitochondrial DNA analysis. Frozen iBAT samples were homogenised in Qiazol (Qiagen) and incubated 
for 5 minutes at room temperature, after which chloroform (Sigma-Aldrich) was added. Following centrifugation, 
total DNA was precipitated from the interphase and the phenol phase with 100% ethanol. After further centrif-
ugation, the resulting DNA pellet was washed in 0.1M sodium citrate, followed by 75% (v/v) ethanol. The DNA 
pellet was air-dried, resuspended in 8mM sodium hydroxide, and neutralised by the addition of HEPES buffer 
and 100 mM EDTA, and stored at −20 °C until use. Relative mitochondrial content was assessed by comparing 
the Ct of mitochondrial Cox2 relative to nuclear β-actin, as described above.
Statistics. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was per-
formed using Origin Pro software (OriginLab). An unpaired Student’s t-test was used for comparison between 
two groups. One-way ANOVA was used when comparing more than two groups, followed by Tukey’s post-hoc 
analysis. A p-value of <0.05 was considered significant. Data was assessed for normality by carrying out standard 
distribution plots. Where there were outliers, sensitivity analysis was performed and analysis repeated with the 
outlier(s) removed.
Study Approval. All experiments were performed in accordance with the Animals (Scientific Procedures) 
Act 1986 Amendment Regulations 2012 and approved by King’s College London’s Animal Welfare and Ethical 
Review Body and the Home Office.
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